Impact of oryzanol plus femoston on efficacy, sleep quality, and quality of life in perimenopausal syndrome patients.

To evaluate the therapeutic impact of Oryzanol combined with Femoston on symptom relief, sleep quality, and quality of life in patients with perimenopausal syndrome (PMS). A total of 201 PMS patients were included and allocated into two groups based on treatment: Femoston monotherapy (control) and Femoston plus Oryzanol (research group). Clinical outcomes were compared, including overall efficacy, adverse events, sex hormone levels, endometrial thickness, bone mineral density (BMD), lipid profiles, neurotransmitter concentrations, sleep quality, and quality of life. The research group demonstrated significantly higher therapeutic efficacy than the control group, with fewer adverse events. Post-treatment improvements were more pronounced in the research group across multiple parameters, including hormonal balance, endometrial thickness, BMD, lipid metabolism, neurotransmitter activity, sleep quality, and overall quality of life (all P<0.05). Co-therapy with Oryzanol and Femoston is highly effective for PMS management. It alleviates neurological symptoms, corrects lipid abnormalities, improves sleep, enhances quality of life, and provides measurable benefits for endometrial and BMD.